Skip to main content

Table 1 Main characteristics of the 14 studies included in the meta-analysis

From: Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis

   Patients (n) Average age (year) Treatment design  
Study Type Con (M/F) Com (M/F) Con Com Con Com JADAD score
Hu 2013 [28] N 21/9 29/14 47.1 45.3 TACE TACE+ Sorafenib 4
Wu 2010 [29] N 21/4 20/5 TACE TACE+ Sorafenib 6
Jiang 2010 [15] R 23/7 24/6 58.0 56.0 TACE TACE+ Sorafenib 4
Chen 2012 [30] R 17/11 20/8 TACE TACE+ Sorafenib 5
Wei 2009 [31] N 22/8 24/6 TACE TACE+ Sorafenib 5
Wei 2012 [16] N 42/2 42/2 53.0 53.0 TACE TACE+ Sorafenib 5
Yu 2011 [32] R 20/5 21/4 45.3 45.3 TACE TACE+ Sorafenib 5
Yang 2013 [33] R TACE TACE+ Sorafenib 5
Ye 2013 [17] N 30/5 32/3 TACE TACE+ Sorafenib 5
Sun 2014 [34] R 66/15 68/13 53.9 ± 8.2 54.5 ± 7.9 TACE TACE+ Sorafenib 5
Zhou 2014 [35] R 31/17 34/14 67.9 ± 10.8 71.9 ± 12.7 TACE TACE+ Sorafenib 5
Wang 2015 [36] R 28 22 TACE TACE+ Sorafenib 5
Lencioni 2016 [13] R 126/27 135/19 63.0 64.5 TACE TACE+ Sorafenib 5
Kudo 2011 [26] R 168/61 174/55 70.0 69.0 TACE TACE+ Sorafenib 5
  1. Note: A total of 1670 patients were included in the meta-analysis. Among these patients, 839 were assigned to the combination group (Com) and treated with TACE plus sorafenib, and 831 were assigned to the control group (Con) and treated with TACE alone
  2. Abbreviations: F female, M male, N non-randomized controlled trials, R randomized controlled trials, and - no description